Novo Nordisk reported a decline in adjusted sales and operating profit for Q1 2026, yet its obesity care segment, particularly the Wegovy pill, showed strong growth and outperformed competitors like Eli Lilly. The company benefits from patent protection for key drugs Ozempic and Wegovy until 2031-2032 in major markets, reducing near-term generic competition risks. Analysts see Novo Nordisk as undervalued with significant upside potential based on discounted cash flow models, supporting a strong buy recommendation despite recent underperformance and challenging guidance for 2026. This outlook is underpinned by the company's long-term growth prospects and competitive advantages.
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges inclu...
Novo Nordisk has experienced an IT security incident involving unauthorized access to some internal systems. The company is investigating with cybersecurity experts and has temporarily taken certain systems offline to protect its environment. While c...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy pill (semaglutide tablets) as the first daily oral GLP-1 treatment for adults with obesity or overweight with weight-related conditions. Based on the OASIS 4 trial,...
About 30 million Americans use GLP-1 drugs, which chemically suppress appetite and reduce fast food demand by 27-30%. This structural shift benefits companies like Amazon, which is expanding its pharmacy and delivery services; Eli Lilly, leading with...
